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INTRODUCTION 
[1] Nanotechnology is the science and technology of manipulating 
molecules and atoms at the molecular level to create devices with new 
molecular properties, organizations and functions.1  Devices such as new 
computers that are billions of times more powerful than any currently 
available2 and boxes the size of sugar cubes that can hold the entire 
content of the Library of Congress are examples of the power of 
nanotechnology.3  Richard Siegal, director of the Rensselaer 
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1
 15 U.S.C. § 7509 (2006). 
2
 Ralph C. Merkle, Nanotechnology: What Will It Mean?, IEEE SPECTRUM, Jan. 1, 2001, 
http://www.spectrum.ieee.org/archive/1494. 
3
 M.C. Roco, Nat’l Science Found., Government Nanotechnology Funding: An 
International Outlook, July 10, 2008, http://www.nsf.gov/crssprgm/nano/reports/ 
roco_vision.jsp. 
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Nanotechnology Center, has predicted “that nanotechnology could cause 
social and industrial rearrangements not unlike the industrial revolution.”4  
While nanotechnology is taking mankind into a future that resembles 
science fiction more and more every day, the law is losing its breath as it 
tries to keep pace with today’s rapid-paced world of technological 
achievement.5   
[2] The first glimpse of nanotechnology occurred in 1959.6  In a 
speech entitled, “There’s Plenty of Room at the Bottom,” Caltech 
physicist Richard Feynman painted his vision of nanotechnology as the 
future of science.7  His hypothesis that scientists could manipulate atoms 
and molecules into building blocks led to the Hollywood hit The Fantastic 
Voyage, which drew on his theory to create a futuristic world where a 
surgical team could be miniaturized and injected into a man’s brain for the 
purpose of operating on a blood clot.8  However, it was not until the 1980s 
that nanotechnology was actually realized with the manipulation of xenon 
atoms to form the letters “IBM.”9 
 
                                                                                                                         
4
 John Miller, Note, Beyond Biotechnology: FDA Regulation of Nanomedicine, 4 COLUM. 
SCI. & TECH. L. REV. 5, ¶ 5 (2003). 
5
 Joel Rothstein Wolfson, Social and Ethical Issues in Nanotechnology: Lessons from 
Biotechnology and Other High Technologies, 22 BIOTECHNOLOGY L. REP. 376, 389 
(2003). 
6
 Miller, supra note 4, at ¶ 3.  See generally Richard P. Feynman, There’s Plenty of Room 
at the Bottom, Address Before the American Physical Society (Dec. 29, 1959), in 
ENGINEERING AND SCIENCE, Feb. 1960, available at http://www.zyvex.com/nanotech/ 
feynman.html (last visited Oct. 24, 2009) (discussing molecular manufacturing). 
7
 See generally Feynman, supra note 6 (discussing the miniaturization of the computer 
and the rearrangement of atoms). 
8
 Miller, supra note 4, at ¶ 3; see FANTASTIC VOYAGE (Twentieth Century-Fox Film 
Corporation 1966). 
9
 See John Walker, Writing With Atoms, http://fourmilab.ch/autofile/ 
www/section2_84_14.html (last visited Oct. 24, 2009). 
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[3] Nanotechnology has come a long way, but researchers are even 
more optimistic for the future.10  Eric Drexler, a leading authority on 
nanotechnology, predicted that “nanomachines will allow scientists to 
prevent death by cellular repair, build spaceships, construct computers the 
size of credit cards that would be billions of times more powerful than 
existing computers, eliminate pollution, rebuild exact plants and animals, 
and effectively produce food to end hunger on the planet.”11  Both the 
government and industry have recognized the impact nanotechnology will 
have and the role it will play in our future.  President Clinton established 
the National Nanotechnology Initiative (NNI) in 2000 when he launched 
the $422 million program to synchronize, at the federal level, the research 
and development concerning nanotechnology.12  States have also begun 
funding research, and universities have even started offering doctorates in 
Nanotechnology.13  Large companies, like HP and IBM, are allocating 
about one-third of their research budget to nanotechnology.14 
[4] With the excitement of new technology, however, comes the task 
of determining how best to regulate it so that it is both safe and effective.  
 
                                                                                                                         
10
 In 1990, there were 1000 scientific publications on nanotechnology and 200 patent 
applications. As of 2002, those numbers had risen to 22,000 and 1900, respectively.  
Jennifer Whitney, Sizing Up the Potential of Nanotechnology: Technology Advances 
Create Opportunity for Revolutionary Medical Applications, But Not Without Some 
Challenges, MED. PROD. OUTSOURCING, Sept. 2007, available at http://www.mpo-
mag.com/articles/2007/09/sizing-up-the-potential-of-nanotechnology.  See generally, 
NAT’L NANOTECH. INITIATIVE, NANOTECHNOLOGY: BIG THINGS FROM A TINY WORLD, 
http://www.nano.gov/Nanotechnology_BigThingsfromaTinyWorld-print.pdf [hereinafter 
NNI]. 
11
 Miller, supra note 4, at ¶ 5.  See generally ERIC K. DREXLER, ENGINES OF CREATION: 
THE COMING ERA OF NANOTECHNOLOGY (1986), available at http://e-drexler.com/d/ 
06/00/EOC/EOC_Table_of_Contents.htm (last visited Oct. 24, 2009) (discussing the 
science and possibilities of nanotechnology). 
12
 Miller, supra note 4, at ¶ 6; NAT’L NANOTECH. INITIATIVE, About the NNI, 
http://www.nano.gov/html/about/home_about.html (last visited Oct. 24, 2009). 
13
 Miller, supra note 4, at ¶ 6. 
14
 Id. at ¶ 7. 
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Many legal issues will inevitably arise concerning ethics, privacy, liability, 
etc.  Part I of this comment will provide a more detailed description of 
nanotechnology; while Part II will branch off into a discussion of a 
specific field within nanotechnology called nanomedicine.  Part III will 
then briefly discuss liability issues that may arise from the use of 
nanomedicine.  Part IV contemplates potential regulatory issues, such as 
who will regulate nanomedicine and what to expect regarding regulations 
for the future.  Part V will follow with some suggests on what might be 
helpful in the way of regulating nanomedicine.   
I.  NANOTECHNOLOGY 
[5] A nanometer (nm) is a unit of measurement equal to one billionth 
of a meter, there being 25,400,000 nm per inch.15  To put that into 
perspective, consider the following examples.  A single sheet of paper is 
about 100,000 nm thick.16  A brunette hair is anywhere from 50,000 to 
100,000 nm in diameter, which is about twice the size of a blond hair, 
which ranges from 15,000 to 50,000 nm across.17   
[6] Nanotechnology is “the science and technology that will enable 
one to understand, measure, manipulate, and manufacture at the atomic, 
molecular, and supramolecular levels, aimed at creating materials, devices, 
and systems with fundamentally new molecular organizations, properties 
and functions.”18  It concerns the scientific knowledge and technical 
capability of manipulating molecules and atoms at dimensions between 
one and one hundred nanometers in order to exploit the properties of a 
 
                                                                                                                         
15
 Larry Berglas, Nanotechnology and the Law: How will Intellectual Property Law 
Adapt to the Development of Nanotechnology?, http://www.uslaw.com/library/article/ 
TNPCommercialCol090600.html?area_id=44 (last visited Oct. 24, 2009); NNI, supra 
note 10, at 2. 
16
 NNI, supra note 10, at 2. 
17
 Id. 
18
 15 U.S.C. § 7509(2) ; see Frederick A. Fiedler & Glenn H. Reynolds, Legal Problems 
of Nanotechnology: An Overview, 3 S. CAL. INTERDISC. L.J. 593, 595 (1994) (noting 
nanotechnology is also referred to as molecular manufacturing). 
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material at the atomic level.19  “Nano[technology] is about redoing 
everything.  Everything when miniaturized will be new.”20   
[7] Nanotechnology is still in the experimental stage, and it may be 
another twenty to thirty years before formal introduction into mainstream 
society.21  Yet, there are already so many promising possibilities on the 
horizon.  Some of these possibilities include materials that have ten times 
the strength of steel but only a fraction of the weight or clothing that 
cleans itself upon exposure to sunlight.22  A company called 3Netics 
Corporation is even working to develop a type of electronic paper 
consisting of thousands of tiny pixels created by using self-assembled 
monolayers of nanoscale materials.23  This technology would allow us to 
download an entire book that would actually look and feel like a real 
book.24  Of all the awe-inspiring, miraculous accomplishments that 
nanotechnology may allow society to achieve, perhaps one of the most 
anticipated and important fields will be that of nanomedicine.   
 
                                                                                                                         
19
 See G. Nagesh Rao, Nanotechnology: A Look Into the Future of Rising Legal 
Dilemmas, 17 ALB. L.J. SCI. & TECH. 835, 839 (2007); Berglas, supra note 15. 
20
 Michael A. Van Lente, Note, Building the New World of Nanotechnology, 38 CASE W. 
RES. J. INT’L L. 173, 176 (2006) (citing Interview with Chad Mirkin, Director, Nw. Univ. 
for Nanotech., in Evanston, Ill. (Dec. 28, 2004), in Rebuilding Things “Atom by Atom”, 
BUS. WK., Dec. 28, 2004, http://www.businessweek.com/bwdaily/dnflash/dec2004/ 
nf20041228_7625_db083.htm). 
21
 Rao, supra note 19, at 838. 
22
 Van Lente, supra note 20, at 173; Berglas, supra note 15 (quoting Bill Clinton, 
President of the United States, Announcement of the National Nanotechnology Initiative 
at the California Institute of Technology (Jan. 21, 2000); see Richard P. Terra, National 
Nanotechnology Initiative in FY 2001 Budget, FORESIGHT UPDATE 40, Mar. 31, 2000, at 
1, available at http://www.foresight.org/Updates/Update40/Update40.1.html. 
23
 Van Lente, supra note 20, at 173. 
24
 Id. 
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II.  NANOMEDICINE 
[8] Nanomedicine is “an offshoot of nanotechnology, referring to 
highly specific medical intervention at the molecular scale for curing 
disease or repairing damaged tissues, such as bone, muscle or nerve.”25  
Using engineered nanodevices and nanostructures, human biological 
systems can be monitored, repaired, constructed and controlled at the 
molecular level.26  In the future, it might be possible to vaccinate people 
with nanoparticles.27  These particles would continuously circulate 
throughout the body, programmed to identify and eliminate certain 
diseases.28  With such nanotechnology, it may eventually be possible to 
eliminate common diseases and alleviate medical pain and suffering.29  
Moreover, all this may happen sooner than one would expect.  Nobel Prize 
winner Richard Smalley forecasted that in the not-too-distant future 
“nanotechnology will have given us specially engineered drugs” that could 
even make cancer “a thing of the past.”30  Others have predicted that there 
 
                                                                                                                         
25
 Shalyn Morrison, Comment, The Unmanned Voyage: An Examination of Nanorobotic 
Liability, 18 ALB. L.J. SCI. & TECH. 229, 231 (2008) (citing National Institute of Health 
Office of Portfolio Analysis and Strategic Initiatives, NIH Roadmap for Medical 
Research: Nanomedicine, http://nihroadmap.nih.gov/nanomedicine).  
26
 Miller, supra note 4, at ¶ 9. 
27
 Alan H. Goldstein, Nanomedicine’s Brave New World, http://dir.salon.com/ 
story/tech/feature/2005/11/28/nanomedicine/index.html (last visited Oct. 24, 2009). 
28See id.; see Ray Kurzweil, Bring on the Nanobots, and We Will Live Long and Prosper, 
THE GUARDIAN, Nov. 22, 2007, at 36, available at http://www.guardian.co.uk/ 
commentisfree/2007/nov/22/comment.comment (noting there have already been 
successful experiments with such first generation devices and that the devices we will 
have twenty-five years from now will be a billion times more powerful than those of 
today). 
29
 Robert A. Freitas, Jr., The Foresight Institute: Nanomedicine FAQ, 
http://www.foresight.org/Nanomedicine/NanoMedFAQ.html#FAQ19 (last visited Oct. 
24, 2009). 
30
 Miller, supra note 4, at 6. 
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would be nanorobots available by 2010 and that we would be capable of 
applying these nanorobots to the healthcare field by 2015.31   
[9] Nanorobots are the “functional devices composed of nanoparts 
with a total size ‘at or below the macrometer range,’” which will create 
and control the other nanotechnology devices.32  Several types of 
nanomedicine creations already exist at the research and development 
stage that could change the way doctors practice medicine.33 
[10] A nanomedical creation falls within one or more of seven 
categories: drugs, drug delivery, diagnostics, devices, gene therapy, cell 
therapy/tissue engineering and nanorobots.34  Nanomedical drugs can be 
engineered to target and destroy things like bacteria or cancerous cells.35 
An example of such a creation is photo thermal nanoshells.36  Nanoshells 
are gold-coated spheres about 130 nm in diameter that are very good at 
absorbing near infrared light, which can harmlessly penetrate several 
inches into the body.37   
 
                                                                                                                         
31
 Morrison, supra note 25, at 238; see Thomas A. Faunce, Nanotechnology in Global 
Medicine and Human Biosecurity: Private Interests, Policy Dilemmas, and the 
Calibration of Public Health Law, 35 J.L. MED. & ETHICS 629, 631 (2007) (predicting 
that clinical use of diagnostic imaging and therapeutic devices will be used individually 
starting about 2010 and in combination around 2020). 
32
 Morrison, supra note 25, at 233, 237; see Jonathan Strickland, How Nanorobots Will 
Work, http://electronics.howstuffworks.com/nanorobot.htm (last visited Oct. 24, 2009) 
(providing a diagram to explain how a nanorobot will operate). 
33
 See Miller, supra note 4, at 6–13. 
34
 Id. 
35
 Id. at 6. 
36
 Rick Weiss, Nanomedicine’s Promise is Anything But Tiny, WASHINGTON POST, Jan. 
31, 2005, at A08, available at http://www.washingtonpost.com/wp-dyn/articles/A49758-
2005Jan30.html (last visited Oct. 24, 2009). 
37
 Id. See generally Surbhi Lal et al., Nanoshell-Enabled Photothermal Cancer Therapy: 
Impending Clinical Impact, 41 ACCTS. OF CHEM. RES. 1842 (2008), available at 
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[11] Scientists have successfully injected nanoshells into the body to 
destroy cancerous tumors without destroying the surrounding, healthy 
tissue.38  Blood vessels are normally leaky around tumors; therefore, once 
nanoshells are injected into the blood stream, they will travel the body 
through the circulatory system, concentrating around tumors.39  Upon 
exposure to the infrared light, the nanoshell would absorb that energy, 
heating up to approximately 122 degrees Fahrenheit, cooking the tumors 
but leaving the healthy tissue unharmed.40  After photo thermal treatment, 
the immune system eliminates the nanoshells from the body.41  The most 
promising fact is that the test subjects are cancer free months after the 
procedure.42   
[12] James K. Baker is a researcher in the field of nanotechnology who 
is working to develop polymer dendrimers, a type of drug delivery 
nanorobot.43  Polymer dendrimers are tree-shaped synthetic molecules 
capable of attaching to certain molecules or carrying molecules 
internally.44  These nanorobots are being designed to infiltrate cells and 
detect pre-malignant and cancerous changes.45  If the changes are detected, 
the nanorobots would release a chemical substance to kill just those 
affected cells and finish the job by verifying the destruction of those 
 
                                                                                                                         
http://pubs.acs.org/doi/full/10.1021/ar800150g?cookieSet=1 (last visited Oct. 24, 2009) 
(providing a more in-depth study of nanoshells). 
38
 Morrison, supra note 25, at 232; Weiss, supra note 36. 
39
 Weiss, supra note 36. 
40
 Id. 
41
 Id. 
42
 Id.; see Lal, supra note 37, at 1846 (reporting that one hundred percent of the mice 
treated with nanoshells were cancer free after ten days). 
43
 Miller, supra note 4, at ¶ 15. 
44
 Id. 
45
 Id. 
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cells.46  Other researchers are working to develop implantable devices that 
would be programmed periodically to dispense certain medicines, like 
insulin or morphine into the body.47   
[13] In the category of Diagnostics, researchers are exploring the 
possibility of nanorobots that can help people in their everyday life, as 
well as in life threatening situations.  On one end of the scale, there is a 
nanodevice being researched called carbon nanotubes.48  These are hollow 
tubes made of interwoven carbon atoms, a hundred times smaller than the 
diameter of a human hair.49  Potential uses of carbon nanotubes include 
implantation under the skin to measure blood sugar, cholesterol, and 
hormone levels, without ever having to extract a drop of blood from the 
body.50  On the other end of the scale, researchers are working on a 
nanodevice that could assist with the diagnosis of cancer.  Quantum Dots 
(Qdots) are crystals composed of periodic materials, which are only ten to 
fifty atoms in diameter.51  Qdots are unique in that they glow a particular 
color when illuminated by ultraviolet light. 52  Which color they glow 
depends on the size of the band gap of the specific Qdot: Qdots two nm in 
size glow bright green, while those that are five nm in size glow red.53  
 
                                                                                                                         
46
 Id. 
47
 Id. at ¶ 16. 
48
 Peter Harris, A Carbon Nanotube Page: Carbon Nanotube Science and Technology, 
http://www.personal.rdg.ac.uk/~scsharip/tubes.htm (defining carbon nanotubes as 
“molecular scale tubes of graphitic carbon” and adding they are “among the strongest 
fibers known”). 
49
 Weiss, supra note 36. 
50
 Id. 
51
 Evident Technologies, How Quantum Dots Work, http://www.evidenttech.com/ 
quantum-dots-explained/180.html (last visited Oct. 24, 2009). 
52
 See id.; Weiss, supra note 36. 
53
 Weiss, supra note 36. 
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These characteristics allow for the possibility of programming Qdots to 
attach to cancer cells, thereby illuminating tumors.54 
[14] Researchers have also discovered that Qdots, when coated with 
particular materials, will attach to specific molecules.55  This characteristic 
makes them excellent tracking devices.56  They can be injected into cells, 
which will then be exposed to ultraviolet light, allowing researchers to 
track the movements of those particular molecules.57  Thus, different sized 
Qdots could be injected simultaneously and allow for more than one 
molecule to be tracked at a time.58  These are merely a few of the 
numerous examples likely to be seen in the future.   
[15] Medical nanorobots are expected to be among the very first types 
of nanotechnology products on the market; because they can save lives 
they will be in high demand.59  This demand will translate into revenues 
that can then be invested in the development of other nanotechnology 
products.60  While it is easy to find ourselves ready to jump on board with 
this promising research, it is best to remember that the actual benefits and 
risks of nanomedicine have yet to be proven.61  We may not always be 
willing to take the risks with the gains. 
 
                                                                                                                         
54
 Id. 
55
 Id. 
56
 See Hitesh R. Patel, Quantum Dots: A Novel Technique for Drug Delivery and 
Therapy, Nov. 17, 2007, http://www.pharmainfo.net/reviews/quantum-dots-novel-
technique-drug-delivery-and-therapy (stating Qdots may be used for tracking for a long 
period without losing fluorescence). 
57
 Weiss, supra note 36. 
58
 Id. 
59
 E-mail Interview with Robert A. Freitas Jr., Member, Lifeboat Foundation, 
http://lifeboat.com/ex/interview.robert.a.freitas.jr (last visited Oct. 24, 2009). 
60
 Id. 
61
 See Morrison, supra note 25, at 231. 
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III.  POTENTIAL ISSUES WITH MEDICAL MALPRACTICE AND  
PRODUCTS LIABILITY 
[16] The extraordinarily small size of nanoproducts results in unusual 
properties that go beyond the normal law of physics, which makes 
working with them quite unpredictable.62  Until an actual nanorobot is 
created and tested on humans, there can only be speculation as to issues of 
liability.63  When it concerns nanomedicine, two parties that are likely to 
be caught in the crosshairs of a lawsuit are the manufacturers and the 
doctors who control the devices.64   
[17] The Restatement of Torts defines a person “subject to liability” as 
an actor, whose conduct is the legal cause of another person’s injury, 
thereby making him liable for that person’s particular claim unless he has 
an applicable defense.65  In a typical products liability case concerning a 
medical device, there is a bright line drawn between the negligence of a 
doctor and a manufacturer.66   
[18] The presumption, generally, is against holding the doctor liable 
and instead turns to the manufacturer of the medical device.67  Under 
products liability law, a manufacturer can be held liable for a defect in 
design, a defect in the manufacture of the product, or due to a failure to 
warn about all of the reasonably foreseeable inherent risks.68  Beginning 
 
                                                                                                                         
62
 Morrison, supra note 25, at 240. 
63
 Id. 
64
 Id. at 230. 
65
 RESTATEMENT (SECOND) OF TORTS  § 5 (1965). 
66
 Morrison, supra note 25, at 240. 
67
 Id. at 242–43. 
68
 John C. Monica, Jr. & Patrick T. Lewis, Preparing for Future Health Litigation: The 
Application of Products Liability Law to Nanotechnology, at 16, 26 (Nov. 3, 2005), 
http://www.nanolawreport.com/tags/powerpoint; cf. John C. Monica, Jr., Products 
Liability in the Age of Nanotechnology: Understanding a Manufacturer’s Duty to Warn, 
Richmond Journal of Law & Technology  Volume XVI, Issue 2 
12 
with a look at design defects, there is bound to be ambiguity in the 
application of the law to nanotechnology.  A manufacturer can be held 
liable for a design defect if the defect made the product unreasonably 
dangerous, and there was a safer and more practicable, reasonable, 
alternative design available at the time of production.69   
[19] When it comes to nanomedical devices, however, it may be 
impossible to determine liability because the small size of the components 
of the device makes it incredibly difficult, if not impossible, to determine 
whether the doctor or manufacturer was negligent.70  There will likely be 
numerous debates on whether nanomedical devices are inherently, 
unreasonably dangerous and whether more primitive, yet proven 
successful, designs are not more practicable by that mere fact.  I predict it 
will be a balancing test between the practicality of using a familiar and 
successful design against the practicality of using a design that is likely to 
be much more effective and fast-acting, albeit its novelty.   
[20] The complexity of nanotechnology may also require a restructuring 
of the law regarding manufacturing defects.  A manufacturing defect 
occurs when the “product departs from its intended design even though all 
possible care was exercised in the preparation and marketing of the 
product.”71  Currently, under the law, “[a] manufacturer is always liable 
for a defectively manufactured product.”72  The complexity of the product 
being manufactured is irrelevant.73  Consequently, manufacturers will be 
taking a risk creating nanotechnology devices because no matter how 
 
                                                                                                                         
Research, and Test (Nov. 2, 2006), http://www.nanolawreport.com/tags/powerpoint 
(providing suggestions to avoid liability using actual example of “Nano Magic”). 
69
 Monica & Lewis, supra note 68, at 17, 23. 
70
 Id. 
71
 Id. at 33.  
72
 Id. at 35. 
73
 Id. 
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complex the design or how unpredictable the consequences, they will be 
held liable if the product malfunctions.   
[21] Finally, I do not predict the failure to warn category to be one 
under which many would file.  This is because nanomedicine will be such 
a new and developing field that patients who agree to be treated by the 
devices are likely going to be thoroughly warned and made to sign waivers 
for quite some time until nanomedicine becomes the norm, if in fact it ever 
does.  If there are any lawsuits under this claim, they would be filed 
against the doctor because when it comes to prescription drugs and 
medical devices, the Learned Intermediary Rule allows a manufacturer to 
“discharge its duty to warn the end-user by warning that person’s doctor,” 
making the doctor responsible for properly warning the patient.74   
[22] Despite the presumption for holding manufacturers liable in 
medcial device lawsuits, the doctors controlling the devices must face 
possible liability for any errors made concerning control of the device.75  
Some nanorobots will be powered by chemicals or the human body 
temperature.76  This begs the question: what happens when the doctor has 
minimal to no control over the functioning of the device?77  Doctors may 
also lack the requisite scientific knowledge to adequately monitor the 
functioning of nanodevices.  Therefore, it may be necessary for hospitals 
to retain nanoexperts to be present during procedures to ensure that the 
nanodevices are functioning properly.78  While this may be very costly, 
 
                                                                                                                         
74
 Id. at 30. 
75
 See Morrison, supra note 25, at 245 (stating that “physicians . . . must observe that 
degree of skill, learning, care, and diligence ordinarily possessed by the average, 
competent practitioner in their professions, and must exercise reasonable and ordinary 
care and diligence in the exercise of such skill and the application of such knowledge.”). 
76
 Id.; see Leslie Rubinstein, A Practical NanoRobot for Treatment of Various Medical 
Problems, The Foresight Institute, http://www.foresight.org/conferences/MNT8/Papers/ 
Rubinstein (last visited Oct. 24, 2009) (listing all the different power sources for 
nanorobots). 
77
 See Morrison, supra note 24, at 242. 
78
 Id. 
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perhaps it is not so far-fetched.  The National Science Foundation has 
predicted the nanotechnology industry will create approximately two 
million new jobs in the next fifteen years.79  These liability dilemmas are 
but a drop in the well of all the issues that will most surely emerge once 
nanomedicine enters into mainstream society.  Because the liability of 
nanorobots is unclear and the future methods of design and control are 
unknown, looking at the bigger picture, today’s policymakers should be 
trying to develop new alternative methods of regulation.80   
IV.  THE REGULATIONS OF THE FOOD AND DRUG ADMINISTRATION 
[23] The unpredictable nature of nanotechnology, as well as its 
potential for harm if abused or misused, necessitates the development of a 
regulation plan for nanotechnology that will foster innovation while 
keeping the public safe.  As noted by Fiedler and Reynolds, “the law of 
unintended consequences operates with a vengeance where technology is 
concerned.”81  When it comes to developing a regulation plan for 
nanomedicine, the focus needs to be on who will be given the 
responsibility to oversee regulation and whether  to operate under the 
current regulations or write new regulations.82   
[24] The future leaps and bounds nanotechnology will be from our 
current methods of manufacturing and pharmacology are analogous to the 
technological progress required to move from burning coal to nuclear 
power production.83  No one would argue that the laws regulating the 
burning of coal would suffice to regulate appropriately the use of nuclear 
energy.  Likewise, our current laws for regulating medical drugs and 
devices will not be adequate to regulate, safely and effectively, the 
 
                                                                                                                         
79
 Id. 
80
 Morrison, supra note 25, at 245. 
81
 Fiedler & Reynolds, supra note 18, at 603. 
82
 Morrison, supra note 25, at 246. 
83
 Fiedler & Reynolds, supra note 18, at 603. 
Richmond Journal of Law & Technology  Volume XVI, Issue 2 
15 
manufacturing and distribution of nanomedicine.  Nevertheless, there is 
currently a debate over that very issue.84   
A.  REGULATION BY THE FOOD AND DRUG ADMINISTRATION 
[25] Under federal law, medical devices are subject to the jurisdiction 
of the FDA, according to the Food, Drug and Cosmetic Act, for the 
purposes of ensuring that they are safe and effective.85  It is foreseeable 
that the FDA will be fully charged with regulating nanomedical devices 
and drugs.86  The FDA will need to be able to determine that the 
nanodevices are safe, that, when used as intended, the probable benefits to 
health will outweigh any possible risks of harm or injury, and that they are 
effective, meaning the products do what they are supposed to do in a 
reliable fashion.87  The FDA must also attempt to balance the promotion 
of timely patient access and the fostering of innovation against the need to 
protect the public’s health by guarding against potentially unsafe 
technologies.88   
[26] The FDA has chosen to attempt regulation of nanomedicine by 
applying current regulations to the emerging technology.89  The FDA 
made a similar decision when it first encountered the issue of regulating 
biotechnology.90  Biotechnology is the “use of living organisms or their 
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products to modify human health and the human environment.”91  When 
first confronted with biotechnology, the FDA did not create any new 
regulations or establish a new center to handle its regulation; it just 
incorporated the biotechnology products into the current regulatory 
scheme by looking at products on a case-by-case basis.92  Before 
attempting to predict issues that might arise by applying the current 
regulatory scheme to nanomedicine products, it is important to look at 
how the FDA functions.   
B.  HOW THE FDA OPERATES 
[27] The FDA is organized into several centers that each specialize in 
regulating particular types of products.93  The ones most likely to be 
involved in the regulation of nanomedicine products are the Center for 
Drug Evaluation and Research (CDER), the Center for Biologics 
Evaluation and Research (CBER), and the Center for Devices and 
Radiological Health (CDRH).94  For purposes of regulation, the FDA 
classifies medical products as either drugs, devices, biologics, or 
combination products.95  When it comes to manufacturing and marketing 
new drugs, a company is required to submit to the FDA an Investigational 
New Drug Application (IND) before it can conduct clinical investigations 
of the drug.96  The purpose of the IND is to provide the FDA with 
information about the drug’s active ingredients and structural formula, as 
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well as its chemistry, manufacturing, and controls information.97  After the 
application is approved, but before the company can file for a New Drug 
Application (NDA) for approval to market the drug,98 the CDER must 
monitor and approve the clinical trials.99  The procedure for biologics is 
substantially the same, except the IND may be submitted to CDER or 
CBER, and the marketing application is labeled a Biologics License 
Application (BLA).100 
[28] The procedure for regulating medical devices is slightly different. 
The CDRH decides whether the device is a Class I, II, or III device 
depending on its level of risk.101  A Class III device is considered to have 
the most risk and is subject to a review of its safety and effectiveness.102  
To obtain FDA approval for a clinical investigation, the manufacturer 
must submit an Application for an Investigational Device Exemption 
(IDE).103  Unlike the procedure for drugs, to be able to market the device, 
the manufacturer must additionally obtain a Premarket approval 
application (PMA), which imposes strict conditions on the manufacturing 
and labeling of the device.104 
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C.  APPLYING FDA REGULATIONS TO NANOSCALE MATERIALS 
[29] The two main problems the FDA is likely to encounter in applying 
its current regulations to nanomedicine products are (1) the issue of 
appropriately placing those products into its present classification scheme 
and (2) maintaining an adequate level of scientific expertise in the 
nanomedicine field.105  It will be difficult to classify these nanorobots 
because many of them have multiple functions.106  For example, a 
nanorobot can be used to clean arterial walls, which would render it a 
device, but this same nanorobot can also administer a cancer-fighting 
treatment, which would make it a drug.107  This particular nanorobot 
would be considered a combination product, but having multiple functions 
is not the main reason classification will be an issue.  Rather, it is the 
miniaturization of medical products that will blur distinctions between 
different categories.108   
[30] The FDA uses a product’s primary mode of action to determine 
how to classify it and to decide which center will have primary jurisdiction 
over the product.109  This is where the current method of classifying 
nanorobots as smaller versions of other products will lead to loopholes in 
regulation.110  Nanomaterials have different chemical and physical 
properties at the molecular level than those of their larger counterparts. 111  
The Federal Food, Drug and Cosmetic Act defines drugs as treatments that 
rely on chemical effects and devices as treatments that operate through 
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mechanical means.112  Such distinctions, however, are not helpful when 
looking at individual atoms.113  “At the atomic level, it becomes virtually 
impossible to separate mechanical from chemical or electrical effects.”114  
Take electrons as an example.  “Electrons have mechanical properties that 
allow them to spin and to maintain their orbits around the atomic nucleus.  
The electrons, which are electrically charged particles, interact to form 
chemical bonds with molecules.”115  These blurred distinctions result in 
difficulties of determining a product’s primary mode of action, which will 
lead to jurisdictional disputes and delays in approving new products.116 
[31] The second problem the FDA will encounter in regulating 
nanomedicine products is maintaining the requisite level of scientific 
expertise.117  Former FDA Commissioner Jane Henney pointed out how 
critical scientific expertise is to regulation: “Those who make decisions at 
the FDA about such traditional or complex and high-tech products must be 
scientifically equal to the intellectual cognitive development that has 
invented these advanced technologies.”118  Because “nanomedicine is a 
technology that will touch virtually every aspect of modern medicine,” 
every center at the FDA will need to develop an enhanced expertise in this 
area.119  Moreover, it will cost a great deal of money to provide education, 
facilities and equipment necessary to achieve the proper level of 
knowledge, and the FDA has been experiencing budget shortfalls.120  Even 
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though universities have recently starting offering doctorates in 
nanotechnology, nanotechnology experts are not very common, and they 
may be lured away be higher salary offers from companies.121   
[32] Despite recent economic shortfalls, the FDA has made an effort to 
educate itself on the topic.  In August of 2006, the FDA launched the 
Nanotechnology Task Force to “identify and recommend ways to address 
knowledge or policy gaps and to facilitate the safe and effective use of 
nanoengineered materials in FDA-regulated products.”122  This Task Force 
investigated topics such as the FDA’s ability to identify products 
containing nanoscale materials, its scope of authority to evaluate the safety 
and effectiveness of such products, and whether the FDA should require or 
permit products to be labeled as nanoscale materials.123 
[33] The Task Force’s research led the FDA to realize that its ability to 
detect nanoscale materials in the body or products is limited and that 
developing the appropriate analytical methods may require a substantial 
effort.124  It concluded that a case-by-case approach should be taken to 
determine whether sufficient evidence exists to prove that a product 
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satisfies the applicable statutory and regulatory standards.125  The Task 
Force also decided it would not be necessary for the FDA to label products 
as containing nanoscale materials because the current science shows 
nanoscale products present no greater safety concerns than other classes of 
products.126   
[34] The FDA Office of Combination Products also created a 
Nanotechnology Interest Group (NTIG), which is composed of 
representatives from all of the centers.127  The goal of its creation was to 
facilitate the regulation of nanotechnology products.128  The FDA will also 
receive guidance from the National Nanotechnology Coordination Office, 
which was established to “serve as the point of contact on Federal 
nanotechnology activities for government organizations, academia, 
industry, professional societies, State nanotechnology programs, interested 
citizen groups, and others to exchange technical and programmatic 
information.”129 
D.  WHY ADEQUATE PREPARATION IS NECESSARY 
[35] If the FDA does not adequately prepare for the regulation of 
nanomedicine products, it could have a negative effect on public health, 
nanomedical research and development and its own efficacy.130  Professor 
Wein contends that the law is responsible for “keeping technology within 
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the bounds of human governance and control.”131  If problems are not 
anticipated and studiously addressed in advance, there is likely to be an 
inappropriate response in regulation.  
[36] Under-regulation could come in the form of hasty approvals of 
dangerous therapies or failures to monitor clinical research effectively, 
exposing patients to a significant risk of harm, mainly because the centers 
involved would not be prepared or know how to identify novel issues 
related to nanomedicine.132  But the lack of preparedness could lead to 
overregulation causing unnecessary delays in patient access.133  FDA 
reviewers confronted with inadequate resources, an inefficient regulatory 
structure, lack of expertise, and growing caseloads may exercise extreme 
caution when reviewing new technology, delaying patient access to 
potentially life-saving and health-enhancing medical devices.134  Such 
ineffective regulation could have a substantial negative impact on 
nanomedical research and development.135   
[37] While too little regulation could cause investors to feel uncertain 
and forestall research, too much regulation could promote “black market” 
research and the loss of scientists to these less scrupulous companies.136  
Additionally, it will likely be difficult, just based on apprehensions about 
the subject matter, to recruit volunteers for clinical trials involving 
nanomedical products; if a poor regulatory decision results in a publicized 
casualty, this could halt the flow of volunteers and, therefore, clinical 
research altogether.137  With no volunteers for clinical trials, companies 
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would not be able to secure FDA approval for marketing, not to mention 
that such a casualty would only fan the flames of opponents of 
nanotechnology in their argument for a legislative ban on all 
nanotechnology research.138  The result of such a showing of inefficacy 
could further reduce confidence in the FDA and the public’s support of 
nanotechnology.139  “Regulators suffer more criticism when a new drug 
causes a single death than they do when the absence of a new drug causes 
a thousand deaths.”140  Therefore, I predict that overregulation will be 
more of a problem than under-regulation.   
V.  SUGGESTIONS FOR REGULATING NANOMEDICAL PRODUCTS 
[38] The nanoscale technology of today is actually relatively simple in 
comparison to the long-term molecular manufacturing that we may 
achieve.141  It has been argued that the risks associated with those longer-
term creations should not be placed on the same level as the 
nanotechnology today for policy consideration purposes.142  Perhaps this 
could facilitate the process by drawing a more narrow focus.  Yet, the two 
biggest issues remain: classification and funding.  There have been 
suggestions that instead of classifying nanoproducts according to their 
primary mode of action, they could be classified based on risk of potential 
harm.143  Another suggestion is to categorize them according to 
function.144  Such categories would include repair (referring to restoration 
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of a previous state), replacement (procedures like organ transplants or 
connecting artificial joints), and augmentation (enhancing cells to perform 
in ways not called for by nature).145  Perhaps using these categories would 
eliminate current problems with classification and alleviate the difficulty 
of creating proper regulations.   
[39] No matter how the FDA determines to handle the issue, funding 
will always be a concern.  Perhaps the best step to take is to persuade 
Congress to increase funding.146  With regard for the potential problems of 
liability, it may also be helpful to create a nanotechnology fund to limit 
liability.147  Such a fund would pay for unforeseen harm caused by 
nanorobots, on the condition that the person not bring a tort claim in 
court.148  By making the payout available for unforeseen harm only, 
manufacturers would be encouraged to exercise due care and doctors to 
safeguard against carelessness.149  This approach would likely ease the 
apprehension of the FDA in approving products.150 
CONCLUSION 
[40] Nanotechnology is within our grasp.  It is better to plan now than 
to suffer the consequences of poor planning later.  Nanotechnology will 
already have enough ethical and legal obstacles to overcome.  For 
instance, nanodevices may become available that will enable constant 
monitoring of a person’s health, opening the door for potential abuse and a 
discussion of how this will affect privacy rights.151  Nanodevices that 
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allow gene alteration, say of hair and eye color, and neurobiochips that 
stimulate brain function, possibly giving the human machine-like qualities, 
will no doubt dredge up ethical debates.152   
[41] Although the FDA appears to be planning to apply the existing 
regulation scheme to nanomedicine, there are likely to be sui generis 
problems only addressable through the creation of entirely new laws.153  
The bottom line is that nanomedicine will bring miraculous benefits as 
well as risks.  Therefore, we should make efforts now to mitigate 
foreseeable problems and insure that nanotechnology will benefit us 
instead of hamper us. 
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